Lipodystrophy: Lessons in lipid and energy metabolism

Current Opinion in Lipidology

Volumn 17, Issue 2, 2006, Pages 162-169

  Simha, Vinaya ^b   Garg, Abhimanyu ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NONE

Author keywords

Dyslipidemia; Insulin resistance; Lipodystrophy; Lipoproteins

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPOCYTOKINE; ADIPONECTIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ESTROGEN; FIBRIC ACID DERIVATIVE; FISH OIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEPTIN; NICOTINIC ACID; ORAL CONTRACEPTIVE AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROTEINASE INHIBITOR; STATINE; TROGLITAZONE;

ADIPOSE TISSUE; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE PREDISPOSITION; DYSLIPIDEMIA; ENERGY METABOLISM; FATTY LIVER; GENETIC HETEROGENEITY; GENOTYPE; HIV ASSOCIATED LIPODYSTROPHY; HOMEOSTASIS; HUMAN; HYPERTRIGLYCERIDEMIA; INHERITANCE; INSULIN RESISTANCE; LIPID METABOLISM; LIPODYSTROPHY; LIPOLYSIS; LIPOPROTEIN SYNTHESIS; LIVER; NONHUMAN; OBESITY; PANCREATITIS; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; RARE DISEASE; REVIEW; SKELETAL MUSCLE;

ADIPOSE TISSUE; DYSLIPIDEMIAS; HUMANS; LIPID METABOLISM; LIPODYSTROPHY;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 33645500068     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mol.0000217898.52197.18     Document Type: Review

References (71)

1. Garg A. Acquired and inherited lipodystrophies. N Engl J Med 2004; 350:1220-1234. A comprehensive review of the clinical features and pathogenetic basis of the different lipodystrophy syndromes.
2. Seip M, Trygstad O. Generalized lipodystrophy, congenital and acquired (lipoatrophy). Acta Paediatr Suppl 1996; 413:2-28.
3. Garg A, Wilson R, Barnes R, et al. A gene for congenital generalized lipodystrophy maps to human chromosome 9q34. J Clin Endocrinol Metab 1999; 84:3390-3394.
4. Agarwal AK, Arioglu E, De Almeida S, et al. AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34. Nat Genet 2002; 31:21-23.
5. Magre J, Delepine M, Khallouf E, et al. Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13. Nat Genet 2001; 28:365-370.
6. Leung DW. The structure and functions of human lysophosphatidic acid acyltransferases. Front Biosci 2001; 6:D944-D953.
7. Simha V, Garg A. Phenotypic heterogeneity in body fat distribution in patients with congenital generalized lipodystrophy caused by mutations in the AGPAT2 or seipin genes. J Clin Endocrinol Metab 2003; 88:5433-5437.
8. Shackleton S, Lloyd DJ, Jackson SN, et al. LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nat Genet 2000; 24:153-156.
9. Cao H, Hegele RA. Nuclear lamin A/C R482Q mutation in Canadian kindreds with Dunnigan-type familial partial lipodystrophy. Hum Mol Genet 2000; 9:109-112.
10. Agarwal AK, Garg A. A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy. J Clin Endocrinol Metab 2002; 87:408-411.
11. Hegele RA, Cao H, Frankowski C, et al. PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy. Diabetes 2002; 51:3586-3590.
12. George S, Rochford JJ, Wolfrum C, et al. A family with severe insulin resistance and diabetes due to a mutation in AKT2. Science 2004; 304:1325-1328. The only reported mutation in the protein kinase AKT2 in a family with autosomal dominant inheritance of diabetes and insulin resistance. The proband showed evidence of partial lipodystrophy.
13. Dunnigan MG, Cochrane MA, Kelly A, et al. Familial lipoatrophic diabetes with dominant transmission. A new syndrome. QJ Med 1974; 43:33-48.
14. Jacob KN, Baptista F, dos Santos HG, et al. Phenotypic heterogeneity in body fat distribution in patients with atypical Werner's syndrome due to heterozygous Arg133Leu lamin A/C mutation. J Clin Endocrinol Metab 2005; 90:6699-6706. The paper reports that the R133L heterozygous LMNA mutation causes phenotypically heterogeneous disorders, including pubertal-onset generalized lipodystrophy and distal partial lipodystrophy. The severity of the metabolic complications correlates with the extent of lipodystrophy.
15. Caux F, Dubosclard E, Lascols O, et al. A new clinical condition linked to a novel mutation in lamins A and C with generalized lipoatrophy, insulin-resistant diabetes, disseminated leukomelanodermic papules, liver steatosis, and cardiomyopathy. J Clin Endocrinol Metab 2003; 88:1006-1013.
16. Chen L, Lee L, Kudlow BA, et al. LMNA mutations in atypical Werner's syndrome. Lancet 2003; 362:440-445.
17. Barroso I, Gurnell M, Crowley VE, et al. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999; 402:880-883.
18. Savage DB, Tan GD, Acerini CL, et al. Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. Diabetes 2003; 52:910-917.
19. Al-Shali K, Cao H, Knoers N, et al. A single-base mutation in the peroxisome proliferator-activated receptor gamma4 promoter associated with altered in vitro expression and partial lipodystrophy. J Clin Endocrinol Metab 2004; 89:5655-5660.
20. Sensenbrenner JA, Hussels IE, Levin LS. A low birthweight syndrome? Rieger syndrome. Birth Defects Orig Artic Ser 1975; 11:423-426.
21. Simha V, Garg A. Body fat distribution and metabolic derangements in patients with familial partial lipodystrophy associated with mandibuloacral dysplasia. J Clin Endocrinol Metab 2002; 87:776-785.
22. Novelli G, Muchir A, Sangiuolo F, et al. Mandibuloacral dysplasia is caused by a mutation in LMNA-encoding lamin A/C. Am J Hum Genet 2002; 71:426-431.
23. Agarwal AK, Fryns JP, Auchus RJ, et al. Zinc metalloproteinase, ZMPSTE24, is mutated in mandibuloacral dysplasia. Hum Mol Genet 2003; 12:1995-2001.
24. Aarskog D, Ose L, Pande H, et al. Autosomal dominant partial lipodystrophy associated with Rieger anomaly, short stature, and insulinopenic diabetes. Am J Med Genet 1983; 15:29-38.
25. Pivnick EK, Angle B, Kaufman RA, et al. Neonatal progeroid (Wiedemann-Rautenstrauch) syndrome: report of five new cases and review. Am J Med Genet 2000; 90:131-140.
26. Misra A, Peethambaram A, Garg A. Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature. Medicine (Baltimore) 2004; 83:18-34. A report on a large case series of patients with APL, and a comprehensive review of all the reported cases. New diagnostic criteria for APL were proposed.
27. Misra A, Garg A. Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature. Medicine (Baltimore) 2003; 82:129-146.
28. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-F58.
29. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352:48-62. An excellent review of the epidemiology, pathophysiology and clinical approach to lipodystrophy in HIV-infected patients on HAART.
30. Carr A, Emery S, Law M, et al. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003; 361:726-735.
31. Chen D, Misra A, Garg A. Clinical review 153: lipodystrophy in human immunodeficiency virus-infected patients. J Clin Endocrinol Metab 2002; 87:4845-4856.
32. Bacchetti P, Gripshover B, Grunfeld C, et al. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 2005; 40:121-131. Although a cross-sectional study, it seeks elegantly to dispel the notion of compensatory lipohypertrophy in LD-HIV patients with fat loss. Strong points of the study include a large sample size, bi-directional questionnaire, cross referencing of body fat measurements and the use of a suitable control group.
33. Agarwal AK, Simha V, Oral EA, et al. Phenotypic and genetic heterogeneity in congenital generalized lipodystrophy. J Clin Endocrinol Metab 2003; 88:4840-4847.
34. Hegele RA, Kraw ME, Ban MR, et al. Elevated serum C-reactive protein and free fatty acids among nondiabetic carriers of missense mutations in the gene encoding lamin A/C (LMNA) with partial lipodystrophy. Arterioscler Thromb Vasc Biol 2003; 23:111-116.
35. Garg A. Gender differences in the prevalence of metabolic complications in familial partial lipodystrophy (Dunnigan variety). J Clin Endocrinol Metab 2000; 85:1776-1782.
36. Heath KV, Hogg RS, Chan KJ, et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS 2001; 15:231-239.
37. Thiebaut R, Daucourt V, Mercie P, et al. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d'Epidemiologie Clinique du Syndrome d'Immunodeficience Acquise en Aquitaine. Clin Infect Dis 2000; 31:1482-1487.
38. Galli M, Cozzi-Lepri A, Ridolfo AL, et al. Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipolCoNa Study. Arch Intern Med 2002; 162:2621-2628.
39. Calza L, Manfredi R, Chiodo F. Hyperlipidaemia in patients with HIV-1 infection receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical course and management. Int J Antimicrob Agents 2003; 22:89-99.
40. Klein S, Jahoor F, Wolfe RR, et al. Generalized lipodystrophy: in vivo evidence for hypermetabolism and insulin-resistant lipid, glucose, and amino acid kinetics. Metabolism 1992; 41:893-896.
41. Beylot M, Sautot G, Laville M, et al. Metabolic studies in lipoatrophic diabetes: mechanism of hyperglycemia and evidence of resistance to insulin of lipid metabolism. Diabete Metab 1988; 14:20-24.
42. Copeland KC, Nair KS, Kaplowitz PB, et al. Discordant metabolic actions of insulin in extreme lipodystrophy of childhood. J Clin Endocrinol Metab 1993; 77:1240-1245.
43. Sekhar RV, Jahoor F, White AC, et al. Metabolic basis of HIV-lipodystrophy syndrome. Am J Physiol Endocrinol Metab 2002; 283:E332-E337.
44. Kissebah AH, Alfarsi S, Adams PW, et al. Role of insulin resistance in adipose tissue and liver in the pathogenesis of endogenous hypertriglyceridaemia in man. Diabetologia 1976; 12:563-571.
45. Barter PJ, Nestel PJ, Carroll KF. Precursors of plasma triglyceride fatty acid in humans. Effects of glucose consumption, clofibrate administration, and alcoholic fatty liver. Metabolism 1972; 21:117-124.
46. Barter PJ, Nestel PJ. Precursors of plasma triglyceride fatty acids in obesity. Metabolism 1973; 22:779-783.
47. Reeds DN, Mittendorfer B, Patterson BW, et al. Alterations in lipid kinetics in men with HIV-dyslipidemia. Am J Physiol Endocrinol Metab 2003; 285:E490-E497.
48. Sekhar RV, Jahoor F, Pownall HJ, et al. Severely dysregulated disposal of postprandial triacylglycerols exacerbates hypertriacylglycerolemia in HIV lipodystrophy syndrome. Am J Clin Nutr 2005; 81:1405-1410. Kinetic studies in six LD-HIV subjects being fed labeled palmitate reveal marked impairment in postprandial disposal and storage of chylomicron triglycerides. This adds to the previous information on accelerated basal lipolysis, helping to clarify the pathophysiological basis of hypertriglyceridemia in LD-HIV.
49. Schmidt HH, Behrens G, Genschel J, et al. Lipid evaluation in HIV-1-positive patients treated with protease inhibitors. Antivir Ther 1999; 4:163-170.
50. Baril L, Beucler I, Valantin MA, et al. Low lipolytic enzyme activity in patients with severe hypertriglyceridemia on highly active antiretroviral therapy. AIDS 2001; 15:415-417.
51. Kannisto K, Sutinen J, Korsheninnikova E, et al. Expression of adipogenic transcription factors, peroxisome proliferator-activated receptor gamma coactivator 1, IL-6 and CD45 in subcutaneous adipose tissue in lipodystrophy associated with highly active antiretroviral therapy. AIDS 2003; 17:1753-1762.
52. Wajchenberg BL, Amancio RF, Santomauro AT, et al. Metabolism of chylomicrons in patients with congenital lipoatrophic diabetes: a study with emulsion models of chylomicrons. Clin Endocrinol (Oxf) 2004; 61:347-352. An investigation into the kinetics of intravenously infused labeled chylomicron-like emulsion in six patients with CGL revealed defective lipolysis and remnant removal.
53. Naito C, Togawa K. A possible role of circulating lipoprotein- triglycerides in the increase in concentration of free fatty acids and in insulin resistance in "total" lipodystrophy. J Clin Endocrinol Metab 1974; 39:1030-1037.
54. Kodama S, Kasuga M, Seki A, et al. Congenital generalized lipodystrophy with insulin-resistant diabetes. Eur J Pediatr 1978; 127:111-119.
55. Enzi G, Digito M, Baldo-Enzi G, et al. Lipid metabolism in lipoatrophic diabetes. Horm Metab Res 1988; 20:587-591.
56. Savage DB, Murgatroyd PR, Chatterjee VK, et al. Energy expenditure and adaptive responses to an acute hypercaloric fat load in humans with lipodystrophy. J Clin Endocrinol Metab 2005; 90:1446-1452. A direct measurement of energy expenditure in response to excess energy consumption in a relatively large group of lipodystrophic subjects. The findings of increased energy expenditure caused by increased fat oxidation offers new insight into the regulation of energy balance, and helps to explain the apparent hypermetabolic state seen in lipodystrophic individuals.
57. Petersen KF, Oral EA, Dufour S, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 2002; 109:1345-1350.
58. Oral EA, Simha V, Ruiz E, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med 2002; 346:570-578.
59. Agarwal AK, Garg A. Congenital generalized lipodystrophy: significance of triglyceride biosynthetic pathways. Trends Endocrinol Metab 2003; 14:214-221.
60. Westerbacka J, Lammi K, Hakkinen AM, et al. Dietary fat content modifies liver fat in overweight nondiabetic subjects. J Clin Endocrinol Metab 2005; 90:2804-2809.
61. Arioglu E, Duncan-Morin J, Sebring N, et al. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med 2000; 133:263-274.
62. Miller J, Brown D, Amin J, et al. A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia. AIDS 2002; 16:2195-2200.
63. Rao A, D'Amico S, Balasubramanyam A, et al. Fenofibrate is effective in treating hypertriglyceridemia associated with HIV lipodystrophy. Am J Med Sci 2004; 327:315-318.
64. Stacpoole PW, Alig J, Kilgore LL, et al. Lipodystrophic diabetes mellitus. Investigations of lipoprotein metabolism and the effects of omega-3 fatty acid administration in two patients. Metabolism 1988; 37: 944-951.
65. Javor ED, Cochran EK, Musso C, et al. Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. Diabetes 2005; 54:1994-2002. An open-label trial of leptin replacement therapy in 15 patients with generalized lipodystrophy revealing significant and sustained improvements in glycemia, dyslipidemia and hepatic steatosis.
66. Javor ED, Ghany MG, Cochran EK, et al. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology 2005; 41:753-760. A report on changes in serum transaminase levels, liver size and fat content, and mean non-alcoholic steatohepatitis score on liver biopsy in lipodystrophic patients on leptin therapy. An improvement in all these parameters was noted, further emphasizing the antisteatotic role of leptin.
67. Simha V, Szczepaniak LS, Wagner AJ, et al. Effect of leptin replacement on intrahepatic and intramyocellular lipid content in patients with generalized lipodystrophy. Diabetes Care 2003; 26:30-35.
68. Routy JP, Smith GH, Blank DW, et al. Plasmapheresis in the treatment of an acute pancreatitis due to protease inhibitor-induced hypertriglyceridemia. J Clin Apher 2001; 16:157-159.
69. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 2002; 16:569-577.
70. Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA 1990; 264:723-726.
71. Haque WA, Vuitch F, Garg A. Post-mortem findings in familial partial lipodystrophy, Dunnigan variety. Diabet Med 2002; 19:1022-1025.